Objective: We aimed to assess the relationship between the Ki-67 index and the risk of recur- rences and survival in patients with breast cancer (BC) that had positive estrogen receptor (ER), positive proges- terone receptor (PR), and negative human epidermal growth factor receptor (HER2).
Patients and Methods: A total of 108 patients who visited the Clinical Oncology Department at Assuit Univer- sity Hospital between 2015 and 2018 were involved in the study. The level of Ki-67 was measured and patients were divided into low Ki-67 (n=62) and high Ki-67 (n=46) groups using 14% as the cut-off value. The Cox-regression hazard model was used for both Univariate and Multivariate analyses. Kaplan-Meier survival curves were used for the survival analysis.
Results: Age, menopausal status, performance status (PS), pathological type, tumor stage (T), nodal stage (N), grade (G), and TNM stage were all analysed in relation to the Ki-67 index; the only statistically significant variable was the T stage (p=0.043). Patients with high Ki-67 level had a greater mortality rate than those with low levels (p=0.004). In comparison to low index groups, the mean disease free survival (DFS) and overall survival (OS) were lower in the high index groups (DFS: 48.41± 4.19 months vs. 64.53± 2.48 months and OS: 54.74± 3.59 months vs. 66.54± 1.99 months with p=0.001 and 0.002, respectively). When compared to the low index group, the high Ki-67 group had a significantly higher incidence of local recurrence (LR) and metastasis (p=0.001).
Conclusions: In patients with positive ER/PR and HER2, negative HER2 BC, the level of Ki-67 strongly inversely correlates with LR/metastasis, DFS, and OS.
To cite this article
Evaluation of ki-67 as independent risk factor and its role in the incidence of local recurrence/distant metastasis in luminal A and luminal B (her2 negative) breast cancer: a retrospective analysis from a single cancer center
Submission date: 03 Jun 2023
Revised on: 17 Jul 2023
Accepted on: 13 Sep 2023
Published online: 27 Sep 2023
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.